<SEC-DOCUMENT>0001193125-25-213602.txt : 20250923
<SEC-HEADER>0001193125-25-213602.hdr.sgml : 20250923
<ACCEPTANCE-DATETIME>20250923171800
ACCESSION NUMBER:		0001193125-25-213602
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250923
DATE AS OF CHANGE:		20250923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mural Oncology plc
		CENTRAL INDEX KEY:			0001971543
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41837
		FILM NUMBER:		251334577

	BUSINESS ADDRESS:	
		STREET 1:		10 EARLSFORT TERRACE
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 T380
		BUSINESS PHONE:		353 1 905 8020

	MAIL ADDRESS:	
		STREET 1:		10 EARLSFORT TERRACE
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 T380

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mural Oncology Ltd
		DATE OF NAME CHANGE:	20230403

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pistachiovale Ltd
		DATE OF NAME CHANGE:	20230329
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d32744ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy
Statement Pursuant to Section&nbsp;14(a) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No. ) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other
than the Registrant&#8194;&#9744; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Mural Oncology plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified in Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check all boxes that apply): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee previously paid with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g32744dsp1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and
Extraordinary General Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;23, 2025 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WALTHAM, Mass. and DUBLIN, Ireland, September&nbsp;23, 2025 (GLOBE NEWSWIRE)&#8211; Mural Oncology plc, (Nasdaq: MURA) (&#8220;<B>Mural</B>&#8221;), a
clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the &#8220;<B>Irish Takeover Rules</B>&#8221;), that it has published the definitive proxy statement of Mural
relating to the Acquisition described below, which also constitutes a scheme circular under Irish law (the &#8220;<B>Proxy Statement</B>&#8221;) and that Mural has commenced mailing the Proxy Statement to Mural shareholders. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced on August&nbsp;20, 2025, XOMA Royalty Corporation (Nasdaq: XOMA) (&#8220;<B>XOMA Royalty</B>&#8221;) and Mural entered into a
definitive transaction agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty (&#8220;<B>Sub</B>&#8221;), has agreed to acquire the entire issued and to be issued share capital of Mural (the
&#8220;<B>Acquisition</B>&#8221;) pursuant to an Irish High Court sanctioned &#8220;scheme of arrangement&#8221; under Chapter 1 of Part 9 of the Irish Companies Act of 2014 (the &#8220;<B>Scheme</B>&#8221;). </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proxy Statement contains important information about the Acquisition for Mural shareholders including, among other things, the full terms and conditions
of the Acquisition, instructions on how Mural shareholders may attend the meetings and vote in respect of the Acquisition, information required under Section&nbsp;452 of the Irish Companies Act 2014 and details of the actions to be taken by Mural
shareholders in relation to the Scheme. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Rule 15(c) of the Irish Takeover Rules, the holders of Mural equity awards have been sent a
proposal describing the treatment of the Mural equity awards in the Acquisition. A copy of the Proxy Statement is also being sent to the holders of Mural equity awards with the Rule 15 proposal for informational purposes only. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of the documents referred to above, and all of the documents required to be made available in accordance with Rule 26 of the Irish Takeover Rules, are
available on Mural&#8217;s website at https://ir.muraloncology.com/strategic-review. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, notices convening the scheme meeting of Mural shareholders
to consider and vote on the Scheme (the &#8220;<B>Scheme Meeting</B>&#8221;) and the related extraordinary general meeting (the &#8220;<B>EGM</B>&#8221;) are contained in the Proxy Statement. The Scheme Meeting will be held on October&nbsp;24, 2025
at 10:30 a.m. Irish local time. Following this meeting, the EGM will be held at 10:45 a.m. Irish local time (or, if the Scheme Meeting has not concluded by 10:45 a.m. Irish local time, as soon as possible after the conclusion or adjournment of the
Scheme Meeting). Both the Scheme Meeting and the EGM will be held at Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Mural </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mural Oncology plc is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of
cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;25, 2025, Mural announced that, based on
the interim analysis of results, its Phase 3 <FONT STYLE="white-space:nowrap">ARTISTRY-7</FONT> trial of nemvaleukin alfa (&#8220;nemvaleukin&#8221;) in combination with pembrolizumab did not achieve its primary endpoint of a statistically
significant improvement in overall survival versus investigator&#8217;s choice chemotherapy. Mural also announced that <FONT STYLE="white-space:nowrap">ARTISTRY-7</FONT> would not continue to final analysis and Mural would cease development of
nemvaleukin for platinum resistant ovarian cancer. On April&nbsp;15, 2025, Mural announced that following review of data from its Phase 2 <FONT STYLE="white-space:nowrap">ARTISTRY-6</FONT> trial of nemvaleukin in mucosal and cutaneous melanoma and
the previously announced results from the <FONT STYLE="white-space:nowrap">ARTISTRY-7</FONT> trial, Mural was discontinuing all clinical development of nemvaleukin and planned to immediately commence an exploration of strategic alternatives focused
on maximizing shareholder value. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more
information, visit Mural Oncology&#8217;s website at www.muraloncology.com. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN,
INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION </B></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS
ANNOUNCEMENT IS BEING MADE PURSUANT TO RULES 17.1(b) AND 15(c) OF THE IRISH TAKEOVER RULES </B></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mural Oncology plc </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@muraloncology.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lucid Capital Markets, LLC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">570 Lexington Ave, 40th Floor
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Offer or Solicitation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement is for information purposes only and is not intended to, and does not, constitute or form part of any recommendation or offer, invitation or
the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities or the solicitation of any proxy, vote or approval in any jurisdiction, whether pursuant to this announcement or otherwise, nor
shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Acquisition is being made solely
by means of a Proxy Statement distributed to Mural&#8217;s shareholders and containing a description of the Scheme and the full terms and conditions of the Acquisition, including details of how Mural&#8217;s shareholders may vote in respect of the
Acquisition. Any decision in respect of, or other response to, the Acquisition, should be made only on the basis of the information contained in the Proxy Statement and the Scheme. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Important Additional Information and Where to Find It </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Acquisition, Mural has filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) a Proxy Statement relating to the Scheme
Meeting and the EGM (which includes the Scheme). The definitive Proxy Statement has been sent to Mural shareholders as of the record date for voting at the Scheme Meeting and EGM. This announcement is not a substitute for the Proxy Statement or any
other document that Mural may file with the SEC or send to its shareholders in connection with the Acquisition. BEFORE MAKING ANY VOTING DECISION, HOLDERS OF MURAL SHARES ARE URGED TO READ THE PROXY STATEMENT (INCLUDING THE SCHEME) ANY AMENDMENTS OR
SUPPLEMENTS THERETO AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE ACQUISITION, INCLUDING ANY DOCUMENTS REFERENCED OR INCLUDED THEREIN, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION
ABOUT THE ACQUISITION, THE PARTIES TO THE SCHEME AND RELATED MATTERS. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any vote in respect of the resolutions proposed at the Scheme Meeting or the EGM to
approve the Acquisition, the Scheme or related matters, or other responses in relation to the Acquisition, should be made only on the basis of the information contained in the Proxy Statement (including the Scheme). The Proxy Statement, as well as
Mural&#8217;s other public filings with the SEC, may be obtained without charge at the SEC&#8217;s website at www.sec.gov and at Mural&#8217;s website https://ir.muraloncology.com/. Mural&#8217;s shareholders will also be able to obtain, without
charge, a copy of the Proxy Statement (including the Scheme) and other relevant documents by directing a written request to Mural, Attn: Chief Legal Officer, Mural Oncology plc, Ten Earlsfort Terrace, D02 T380, Dublin 2, Ireland or by phone to +353
1 920 1000 or by contacting Investor Relations, via email at ir@muraloncology.com. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Participants in the Solicitation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mural and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from Mural&#8217;s
shareholders in connection with the Acquisition and any other matters to be voted on at the Scheme Meeting or the EGM. Information about the directors and executive officers of Mural, including a description of their direct or indirect interests, by
security holdings or otherwise, is set forth in the Proxy Statement and in Mural&#8217;s definitive proxy statement on Schedule 14A for its 2025 annual general meeting of shareholders, filed with the SEC on April&nbsp;28, 2025. Other information
regarding the persons who may, under the rules of the SEC, be deemed to be participants in the solicitation of Mural&#8217;s shareholders, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth
in the Proxy Statement and other relevant materials filed with the SEC in connection with the Acquisition. You may obtain free copies of these documents using the sources indicated above. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cautionary Note Regarding Forward-Looking Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements contained in this announcement regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of
the Private Securities Litigation Reform Act of 1995 with respect to Mural, XOMA Royalty or Sub. Forward-looking statements are intended to be identified by words such as &#8220;anticipate&#8221;, &#8220;target&#8221;, &#8220;expect&#8221;,
&#8220;estimate&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;believe&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;would&#8221;, &#8220;could&#8221; or &#8220;should&#8221; or other words of similar meaning or the negative
thereof. Forward-looking statements include but are not limited to statements regarding Mural, XOMA Royalty and Sub&#8217;s intention to consummate the Acquisition, the approval of the Acquisition by Mural&#8217;s shareholders, the payment of any
Additional Price Per Share to Mural&#8217;s shareholders, and the expected timing of the Closing. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements. Risks and uncertainties that may cause actual results to differ from
expectations include: uncertainties as to the timing and completion of the Scheme Meeting and EGM; uncertainties as to the approval by Mural&#8217;s shareholders of the required resolutions at the Scheme Meeting and the EGM; the possibility that
closing conditions for the Acquisition may not be satisfied or waived, including the failure to receive sanction of the Scheme by the High Court; risks that ongoing costs to Mural will result in Mural&#8217;s actual closing net cash on the Closing
Net Cash Calculation Date not exceeding the Estimated Closing Net Cash, which will mean that no Additional Price Per Share is paid to Mural&#8217;s shareholders; the other risks and uncertainties pertaining to Mural&#8217;s business, including those
described in Mural&#8217;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC, as well as Mural&#8217;s subsequent filings with
the SEC, including the Proxy Statement; and other potential risks and uncertainties related to XOMA Royalty, including those described in more detail in XOMA Royalty&#8217;s most recent Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> and its other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All subsequent oral or written
forward-looking statements attributable to Mural, XOMA Royalty or Sub or any persons acting on their behalf are expressly qualified in their entirety by the cautionary statement above. None of Mural, XOMA Royalty or Sub undertake any obligation to
update or revise the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Responsibility Statement Required by the Irish Takeover Rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of the Mural Board of Directors accept responsibility for the information contained in this announcement. To the best of the knowledge and belief
of the members of the Mural Board of Directors (who, in each case, have taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect
the import of such information. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Profit Forecast or Merger Benefit Statement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No statement in this announcement is intended to constitute a profit forecast or profit estimate for any period, nor should any statement be interpreted to
mean that earnings or earnings per share of Mural will, for the current or future financial years or other periods, necessarily match or be greater or lesser than those for the relevant preceding financial periods. No statement in this announcement
constitutes an asset valuation or a quantified financial benefits statement within the meaning of the Irish Takeover Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure Requirements
of the Irish Takeover Rules </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Rule 8.3(b) of the Irish Takeover Rules, any person who is, or becomes, &#8220;interested&#8221; (directly or
indirectly) in 1% or more of any class of &#8220;relevant securities&#8221; of Mural must disclose all &#8220;dealings&#8221; in such &#8220;relevant securities&#8221; during the &#8220;offer period&#8221;. The disclosure of a &#8220;dealing&#8221;
in &#8220;relevant securities&#8221; by a person to whom Rule 8.3(b) applies must be made by no later than 3:30pm (U.S. Eastern Time) on the &#8220;business day&#8221; following the date of the relevant &#8220;dealing&#8221;. A dealing disclosure
must contain the details specified in Rule 8.6(b) of the Irish Takeover Rules, including details of the dealing concerned and of the person&#8217;s interests and short positions in any &#8220;relevant securities&#8221; of Mural. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All &#8220;dealings&#8221; in &#8220;relevant securities&#8221; of Mural by a bidder, or by any party acting in concert with a bidder, must also be disclosed
by no later than 12:00 noon (U.S. Eastern Time) on the &#8220;business day&#8221; following the date of the relevant &#8220;dealing&#8221;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If two or
more persons <FONT STYLE="white-space:nowrap">co-operate</FONT> on the basis of an agreement, either express or tacit, either oral or written, to acquire an &#8220;interest&#8221; in &#8220;relevant securities&#8221; of Mural, they will be deemed to
be a single person for the purpose of Rule 8.3(a) and (b)&nbsp;of the Irish Takeover Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A disclosure table, giving details of the companies in whose
&#8220;relevant securities&#8221; dealing disclosures should be made, can be found on the Irish Takeover Panel&#8217;s website at www.irishtakeoverpanel.ie. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Interests in securities&#8221; arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of
securities. In particular, a person will be treated as having an &#8220;interest&#8221; by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terms in quotation marks in this section are defined in the Irish Takeover Rules, which can also be found on the Irish Takeover Panel&#8217;s website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are in any doubt as to whether or not you are required to disclose a &#8220;dealing&#8221; under Rule 8, please consult the Irish Takeover
Panel&#8217;s website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The release, publication or distribution of this announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions.
Accordingly, copies of this announcement and all other documents relating to the Acquisition are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such restricted jurisdictions.
Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent
permitted by applicable law, each of Mural, XOMA Royalty and Sub disclaims any responsibility or liability for the violations of any such restrictions by any person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this announcement will be available, free of charge (subject to certain restrictions
relating to persons resident in certain Restricted Jurisdictions) on Mural&#8217;s website at&nbsp;https://ir.muraloncology.com/strategic-review&nbsp;by no later than 12:00 noon (U.S. Eastern Time) on the business day following publication of this
announcement. Neither the content of the websites referred to in this announcement nor the content of any other websites accessible from hyperlinks on such websites is incorporated into, or forms part of, this announcement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g32744dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g32744dsp1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "3 )4# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
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M!(-R21G((KYJ47%VDM3]=I585H*I3=T^J)N<U)J'6@!: "@ H 0G%  !^=
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M;3+F.ZB,/EW+ ,20>@\QI#]"!VJL;@JM3+HJJO?A^7_#"HUX1Q+Y/AD>B_\
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MM]2LW (FMI Z\C/;ZU\'4I3I/EFK,^]I5:=:/-3=T:M9&H4 % !0 4 % !0
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M:!K$](6@ H 0\<T  .: /EW]JW]CFQ^+HE\3>&8XM/\ %B)^^10%2^ Z;O\
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MUM8AM2*)0JBOE9SE4DY3=V?N^%PM'!4HT,/!1BMDM"U4'4% "T % !0 4 %
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= =0 4 % !0 4 % !0 T')- #J "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
